A special issue of the Journal of Neurotrauma, published on March 15, 2016, features eight manuscripts from the Operation Brain Trauma Therapy multi-site research consortium, and was guest-edited by Patrick Kochanek, lead investigator of the OBTT. The issue also features an introduction by Colonel Todd E. Rasmussen, MD, Director of the Combat Casualty Care Research Program (CCCRP), Fort Detrick, MD.
The OBTT identifies and tests novel therapies for TBI in multiple animal models, and is composed of six sites: the University of Pittsburgh School of Medicine, the University of Miami Miller School of Medicine, the Walter Reed Army Institute of Research, the Medical College of Virginia Campus of Virginia Commonwealth University, the University of Florida, Messina University, Italy, and Banyan Biomarkers, LLC.
Out of the five therapies recently tested by the OBTT, the anti-epileptic drug levetiracetam was found to be the most promising for future clinical trials, according to a press release from Mary Ann Liebert, Inc., publishers. This article summarizing this trial was lead-authored by Megan Browning, one of our former pediatric fellows and Safar Center trainees, who is currently an intensivist with Essentia Health of Duluth, MN.
“OBTT has assembled a highly talented and respected team of TBI investigators,” notes Kochanek, “who have worked diligently to—for the first time—compare multiple therapies and biomarkers across multiple TBI models and centers in the pre-clinical arena.” Kochanek also emphasizes that the “results do not reflect in any way the desire for OBTT to represent a bully pulpit or the answer to defining optimal candidate therapies for clinical evaluation. Rather, it is hoped that the field views the collective work as providing valuable clues to future directions for both clinical and additional pre-clinical investigations toward the successful development of a new neuroprotective therapy for TBI.”
Thumbnail image courtesy of Mary Ann Liebert, Inc., publishers.